Cargando…

Management of Lupus Nephritis

Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamirou, Farah, Houssiau, Frédéric A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916202/
https://www.ncbi.nlm.nih.gov/pubmed/33572385
http://dx.doi.org/10.3390/jcm10040670
_version_ 1783657425504567296
author Tamirou, Farah
Houssiau, Frédéric A.
author_facet Tamirou, Farah
Houssiau, Frédéric A.
author_sort Tamirou, Farah
collection PubMed
description Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials.
format Online
Article
Text
id pubmed-7916202
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79162022021-03-01 Management of Lupus Nephritis Tamirou, Farah Houssiau, Frédéric A. J Clin Med Review Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials. MDPI 2021-02-09 /pmc/articles/PMC7916202/ /pubmed/33572385 http://dx.doi.org/10.3390/jcm10040670 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tamirou, Farah
Houssiau, Frédéric A.
Management of Lupus Nephritis
title Management of Lupus Nephritis
title_full Management of Lupus Nephritis
title_fullStr Management of Lupus Nephritis
title_full_unstemmed Management of Lupus Nephritis
title_short Management of Lupus Nephritis
title_sort management of lupus nephritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916202/
https://www.ncbi.nlm.nih.gov/pubmed/33572385
http://dx.doi.org/10.3390/jcm10040670
work_keys_str_mv AT tamiroufarah managementoflupusnephritis
AT houssiaufrederica managementoflupusnephritis